"Patients with CLL harboring 17p deletion [del(17p)] are considered to have very poor prognosis. Venetoclax is an orally bioavailable, selective BCL-2 inhibitor that induces apoptosis in CLL cells independent of p53. A phase 1 study of Venetoclax showed high response rates in patients with relapsed/refractory CLL, including del(17p) CLL (overall response rate, ORR = 77%). This pivotal phase 2, single-arm, multicenter study evaluated Venetoclax monotherapy in patients with relapsed/refractory del(17p) CLL"
Of the 107 enrolled patients, "all pts but one had del(17p); 60 of 83 pts with available data (72.3%) had mutated TP53.
:
Undetectable MRD was observed in >20% of responders. More than 10% of all patients achieved independently assessed deep responses (CR, CRi, or nPR). Such depths of response have not been previously reported for this population. "
ash.confex.com/ash/2015/web...
Pretty impressive results after a median of 12 months time on the trial for a tough to treat group of patients!!
Neil
Survey for CLL patients having taken Venetoclax or Acalabrutinib
